[1]

Zhang S, Yu Q, Li Z, Zhao Y, Sun Y. 2024. Protein neddylation and its role in health and diseases. Signal Transduction and Targeted Therapy 9:85

doi: 10.1038/s41392-024-01800-9
[2]

Lu X, Kong X, Wu H, Hao J, Li S, et al. 2023. UBE2M-mediated neddylation of TRIM21 regulates obesity-induced inflammation and metabolic disorders. Cell Metabolism 35:1390−1405.e8

doi: 10.1016/j.cmet.2023.05.011
[3]

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, et al. 2009. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732−736

doi: 10.1038/nature07884
[4]

Serrano-Maciá M, Simón J, González-Rellan MJ, Azkargorta M, Goikoetxea-Usandizaga N, et al. 2021. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Molecular Metabolism 53:101275

doi: 10.1016/j.molmet.2021.101275
[5]

Park HS, Ju UI, Park JW, Song JY, Shin DH, et al. 2016. PPARγ neddylation essential for adipogenesis is a potential target for treating obesity. Cell Death & Differentiation 23:1296−1311

doi: 10.1038/cdd.2016.6
[6]

Gonzalez-Rellan MJ, Fernández U, Parracho T, Novoa E, Fondevila MF, et al. 2023. Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism. Cell Metabolism 35:1630−1645.e5

doi: 10.1016/j.cmet.2023.07.003
[7]

Ren H, Luan Z, Zhang R, Zhang H, Bian C. 2024. A novel approach to explore metabolic diseases: neddylation. Pharmacological Research 210:107532

doi: 10.1016/j.phrs.2024.107532
[8]

Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, et al. 2022. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. Journal of Hematology & Oncology 15:56

doi: 10.1186/s13045-022-01264-w
[9]

Gu L, Du Y, Nazmul Hasan M, Clayton YD, Li T. 2025. Adipose cullin 3 mediates the antiobesity effect of pan neddylation inhibitors. Proceedings of the National Academy of Sciences of the United States of America 122:e2515947122

doi: 10.1073/pnas.2515947122
[10]

Gu L, Du Y, Chen J, Hasan MN, Clayton YD, et al. 2024. Cullin 3 RING E3 ligase inactivation causes NRF2-dependent NADH reductive stress, hepatic lipodystrophy, and systemic insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 121:e2320934121

doi: 10.1073/pnas.2320934121
[11]

Chen C, Gu L, Matye DJ, Clayton YD, Hasan MN, et al. 2022. Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization. Proceedings of the National Academy of Sciences of the United States of America 119:e2111737119

doi: 10.1073/pnas.2111737119
[12]

Ju UI, Jeong DW, Seo J, Park JB, Park JW, et al. 2020. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment. Cell Death & Disease 11:283

doi: 10.1038/s41419-020-2472-6
[13]

Ni HM, Woolbright BL, Williams J, Copple B, Cui W, et al. 2014. Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. Journal of Hepatology 61:617−625

doi: 10.1016/j.jhep.2014.04.043
[14]

He Z, Yuan Z, Yang F, Zhang J, Zhao W, et al. 2024. A comprehensive review on DCN1 protein, inhibitors and their therapeutic applications. International Journal of Biological Macromolecules 277:134541

doi: 10.1016/j.ijbiomac.2024.134541
[15]

He ZX, Gao G, Qiao H, Dong GJ, Dan Z, et al. 2024. Discovery of 1,2,4-triazole-3-thione derivatives as potent and selective DCN1 inhibitors for pathological cardiac fibrosis and remodeling. Journal of Medicinal Chemistry 67:18699−18723

doi: 10.1021/acs.jmedchem.4c00713